Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TATE and Pembrolizumab in Liver Metastatic Colorectal and Non-Small Cell Lung Cancer
NCT04701476Phase 2Recruiting
- Sponsor
- Teclison
- Start
- May 2021
- Primary completion
- Mar 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of tirapazamine, pembrolizumab in colorectal cancer (CRC), non-small cell lung cancer (NSCLC), sponsored by Teclison. Started May 2021; status: recruiting.
02
Drugs
tirapazaminepembrolizumab
03
Conditions
colorectal cancer (CRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04701476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04701476.